S&P 500   4,283.06 (+0.36%)
DOW   33,755.37 (+0.27%)
QQQ   352.37 (+1.02%)
AAPL   179.17 (+0.76%)
MSFT   326.10 (+0.84%)
META   265.64 (+0.77%)
GOOGL   122.84 (+0.28%)
AMZN   125.07 (+3.17%)
TSLA   230.93 (+2.83%)
NVDA   384.40 (+2.58%)
NIO   7.67 (-1.16%)
BABA   86.80 (+1.78%)
AMD   120.02 (+1.86%)
T   15.95 (-0.93%)
F   13.51 (-0.59%)
MU   64.30 (-4.12%)
CGC   0.71 (-2.37%)
GE   106.66 (+0.55%)
DIS   92.23 (-0.31%)
AMC   4.61 (-2.54%)
PFE   39.01 (+0.31%)
PYPL   64.59 (+0.86%)
NFLX   405.00 (+1.31%)
S&P 500   4,283.06 (+0.36%)
DOW   33,755.37 (+0.27%)
QQQ   352.37 (+1.02%)
AAPL   179.17 (+0.76%)
MSFT   326.10 (+0.84%)
META   265.64 (+0.77%)
GOOGL   122.84 (+0.28%)
AMZN   125.07 (+3.17%)
TSLA   230.93 (+2.83%)
NVDA   384.40 (+2.58%)
NIO   7.67 (-1.16%)
BABA   86.80 (+1.78%)
AMD   120.02 (+1.86%)
T   15.95 (-0.93%)
F   13.51 (-0.59%)
MU   64.30 (-4.12%)
CGC   0.71 (-2.37%)
GE   106.66 (+0.55%)
DIS   92.23 (-0.31%)
AMC   4.61 (-2.54%)
PFE   39.01 (+0.31%)
PYPL   64.59 (+0.86%)
NFLX   405.00 (+1.31%)
S&P 500   4,283.06 (+0.36%)
DOW   33,755.37 (+0.27%)
QQQ   352.37 (+1.02%)
AAPL   179.17 (+0.76%)
MSFT   326.10 (+0.84%)
META   265.64 (+0.77%)
GOOGL   122.84 (+0.28%)
AMZN   125.07 (+3.17%)
TSLA   230.93 (+2.83%)
NVDA   384.40 (+2.58%)
NIO   7.67 (-1.16%)
BABA   86.80 (+1.78%)
AMD   120.02 (+1.86%)
T   15.95 (-0.93%)
F   13.51 (-0.59%)
MU   64.30 (-4.12%)
CGC   0.71 (-2.37%)
GE   106.66 (+0.55%)
DIS   92.23 (-0.31%)
AMC   4.61 (-2.54%)
PFE   39.01 (+0.31%)
PYPL   64.59 (+0.86%)
NFLX   405.00 (+1.31%)
S&P 500   4,283.06 (+0.36%)
DOW   33,755.37 (+0.27%)
QQQ   352.37 (+1.02%)
AAPL   179.17 (+0.76%)
MSFT   326.10 (+0.84%)
META   265.64 (+0.77%)
GOOGL   122.84 (+0.28%)
AMZN   125.07 (+3.17%)
TSLA   230.93 (+2.83%)
NVDA   384.40 (+2.58%)
NIO   7.67 (-1.16%)
BABA   86.80 (+1.78%)
AMD   120.02 (+1.86%)
T   15.95 (-0.93%)
F   13.51 (-0.59%)
MU   64.30 (-4.12%)
CGC   0.71 (-2.37%)
GE   106.66 (+0.55%)
DIS   92.23 (-0.31%)
AMC   4.61 (-2.54%)
PFE   39.01 (+0.31%)
PYPL   64.59 (+0.86%)
NFLX   405.00 (+1.31%)
NASDAQ:INFI

Infinity Pharmaceuticals (INFI) Stock Forecast, Price & News

$0.19
0.00 (-0.05%)
(As of 11:05 AM ET)
Compare
Today's Range
$0.18
$0.19
50-Day Range
$0.14
$0.20
52-Week Range
$0.12
$1.76
Volume
4,148 shs
Average Volume
858,601 shs
Market Capitalization
$16.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.50

Infinity Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
689.5% Upside
$1.50 Price Target
Short Interest
Healthy
0.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.24mentions of Infinity Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.46) to ($0.55) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.44 out of 5 stars

Medical Sector

904th out of 981 stocks

Pharmaceutical Preparations Industry

449th out of 483 stocks


INFI stock logo

About Infinity Pharmaceuticals (NASDAQ:INFI) Stock

Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. It focuses on its drug development segment. The company was founded by Steven H. Holtzman and Matthew D. Shair on March 22, 1995 and is headquartered in Cambridge, MA.

Receive INFI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Infinity Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INFI Stock News Headlines

New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
INFI Infinity Pharmaceuticals, Inc.
See More Headlines

INFI Price History

INFI Company Calendar

Last Earnings
3/28/2023
Today
6/08/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INFI
CUSIP
45665G30
Employees
23
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$1.50
High Stock Price Forecast
$1.50
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+702.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-44,370,000.00
Net Margins
-1,608.46%
Pretax Margin
-1,608.46%

Debt

Sales & Book Value

Annual Sales
$2.59 million
Book Value
($0.21) per share

Miscellaneous

Free Float
81,085,000
Market Cap
$16.80 million
Optionable
Optionable
Beta
1.36

Social Links


Key Executives

  • Adelene Q. Perkins
    Chairman, Chief Executive & Financial Officer
  • Stéphane Peluso
    Chief Scientific Officer
  • Robert Ilaria
    Chief Medical Officer
  • Seth A. Tasker
    Secretary, Chief Business Officer & Senior VP
  • Jennifer Roberts
    Vice President-Clinical Operations













INFI Stock - Frequently Asked Questions

Should I buy or sell Infinity Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" INFI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INFI, but not buy additional shares or sell existing shares.
View INFI analyst ratings
or view top-rated stocks.

What is Infinity Pharmaceuticals' stock price forecast for 2023?

2 Wall Street research analysts have issued 12 month price objectives for Infinity Pharmaceuticals' stock. Their INFI share price forecasts range from $1.50 to $1.50. On average, they expect the company's stock price to reach $1.50 in the next twelve months. This suggests a possible upside of 702.6% from the stock's current price.
View analysts price targets for INFI
or view top-rated stocks among Wall Street analysts.

How have INFI shares performed in 2023?

Infinity Pharmaceuticals' stock was trading at $0.5550 at the beginning of the year. Since then, INFI shares have decreased by 66.3% and is now trading at $0.1869.
View the best growth stocks for 2023 here
.

Are investors shorting Infinity Pharmaceuticals?

Infinity Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 619,800 shares, an increase of 7.5% from the April 30th total of 576,700 shares. Based on an average daily volume of 1,180,000 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.7% of the company's shares are short sold.
View Infinity Pharmaceuticals' Short Interest
.

When is Infinity Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our INFI earnings forecast
.

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) released its earnings results on Tuesday, March, 28th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. The biotechnology company earned $0.54 million during the quarter, compared to the consensus estimate of $11.88 million. Infinity Pharmaceuticals had a negative trailing twelve-month return on equity of 956.26% and a negative net margin of 1,608.46%.

What is Adelene Q. Perkins' approval rating as Infinity Pharmaceuticals' CEO?

10 employees have rated Infinity Pharmaceuticals Chief Executive Officer Adelene Q. Perkins on Glassdoor.com. Adelene Q. Perkins has an approval rating of 100% among the company's employees. This puts Adelene Q. Perkins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Infinity Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Novavax (NVAX) and Celldex Therapeutics (CLDX).

What is Infinity Pharmaceuticals' stock symbol?

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

Who are Infinity Pharmaceuticals' major shareholders?

Infinity Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.63%), Renaissance Technologies LLC (0.26%), Virtu Financial LLC (0.20%), Wittenberg Investment Management Inc. (0.19%) and Susquehanna International Group LLP (0.00%).
View institutional ownership trends
.

How do I buy shares of Infinity Pharmaceuticals?

Shares of INFI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Infinity Pharmaceuticals' stock price today?

One share of INFI stock can currently be purchased for approximately $0.19.

How much money does Infinity Pharmaceuticals make?

Infinity Pharmaceuticals (NASDAQ:INFI) has a market capitalization of $16.80 million and generates $2.59 million in revenue each year. The biotechnology company earns $-44,370,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

How can I contact Infinity Pharmaceuticals?

Infinity Pharmaceuticals' mailing address is 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138. The official website for the company is www.infi.com. The biotechnology company can be reached via phone at (617) 453-1000, via email at irpr_info@infi.com, or via fax at 617-453-1001.

This page (NASDAQ:INFI) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -